The transcriptional programs that guide lymphocyte differentiation depend on the precise expression and timing of transcription factors (TFs). The TF BACH2 is essential for T and B lymphocytes and is associated with an archetypal super-enhancer (SE). Single-nucleotide variants in the BACH2 locus are associated with several autoimmune diseases, but BACH2 mutations that cause Mendelian monogenic primary immunodeficiency have not previously been identified. Here we describe a syndrome of BACH2-related immunodeficiency and autoimmunity (BRIDA) that results from BACH2 haploinsufficiency. Affected subjects had lymphocyte-maturation defects that caused immunoglobulin deficiency and intestinal inflammation. The mutations disrupted protein stability by interfering with homodimerization or by causing aggregation. We observed analogous lymphocyte defects in Bach2-heterozygous mice. More generally, we observed that genes that cause monogenic haploinsufficient diseases were substantially enriched for TFs and SE architecture. These findings reveal a previously unrecognized feature of SE architecture in Mendelian diseases of immunity: heterozygous mutations in SE-regulated genes identified by whole-exome/genome sequencing may have greater significance than previously recognized.
The inheritance patterns of genetic diseases fall along a spectrum that ranges from the vast majority, representing polygenic susceptibility variants (usually identified in genome-wide associate studies (GWAS)), to the minority, which are monogenic and manifest in either a recessive or a dominant manner. It is now appreciated that mutations in more than 300 different genes can cause primary immunodeficiencies (PIDs), many of which affect the function of T and B lymphocytes [1] [2] [3] [4] . PIDs are often paradoxically associated with autoimmunity [3] [4] [5] [6] [7] . Common variable immunodeficiency (CVID), a major form of PID with antibody deficiency, is typically associated with recurrent infections and autoimmunity 8 . Recently developed gene-sequencing technologies now allow for the rapid identification of PIDs, but they have also raised the important question of how to interpret the many heterozygous mutations seen in both affected individuals and healthy controls. Relatively few PID syndromes are caused by haploinsufficiency, an autosomal dominant pattern of disease inheritance in which one allele is damaged and only a single functional allele remains 9 . Genes such as CTLA4 are particularly susceptible to haploinsufficiency, although the reasons for this are unknown 10 . Given that many healthy people harbor heterozygous loss-of-function or hypomorphic variants, why should partial changes in gene expression have significant consequences for health? 8 1 4 VOLUME 18 NUMBER 7 JULY 2017 nature immunology
A r t i c l e s
Promoters and enhancer elements govern gene expression. Most genes, such as the housekeeping gene ACTB, are regulated by a limited number of associated enhancers, known as 'typical enhancers' 11 . By contrast, 5-10% of genes have a complex enhancer structure consisting of multiple enhancers that collectively are described as SEs 12, 13 . Genes with associated SEs have a highly regulated pattern of gene expression; single-nucleotide polymorphisms shown to be associated with autoimmune diseases in GWAS are preferentially enriched in SE regions 14 . These findings suggest that minor changes in regulatory function at SE regions could have significant consequences for genes regulated by SEs, and thus potentially for the immune system.
BACH2 is a typical example of an SE-regulated gene associated with autoimmune disease. The protein it encodes is a highly conserved member of the basic leucine zipper (bZIP)-domain superfamily of TFs, and a critical regulator of differentiation and maturation in both T and B lymphocytes 15, 16 . Polymorphisms in the human gene locus are associated with several autoimmune diseases, including asthma 17 , insulin-dependent diabetes mellitus 18 , Crohn's and celiac diseases 19, 20 , vitiligo 21 and multiple sclerosis 16, 22 . The Bach2 gene locus has the largest SE structure seen in mouse lymphocytes 14 . Homozygous deletion of Bach2 in mice results in spontaneous fatal autoimmunity between 3 and 9 months of age 15 . Functionally, BACH2 acts as a repressive 'guardian' TF that regulates the balance among a network of other TFs critical to the specification and maturation of T and B cells. In B cells, BACH2 controls the balance between PAX5 and BLIMP1 by repressing the latter 23, 24 to decelerate plasma cell differentiation and permit antibody class-switch recombination (CSR) (thereby allowing the expression of IgA, IgG and IgE isotypes) 25 . Consequently, mice that lack BACH2 have B cells with impaired CSR that rapidly differentiate into IgM-restricted plasma cells. In T cells, BACH2 regulates networks of genes that control effector T cell lineages 14 and cellular senescence 26 , thus limiting differentiation into effector T cells 15 and promoting the development of FoxP3 + regulatory T cells (T reg cells). T reg cells are a nonredundant suppressive lineage of T cells that prevent the development of autoimmune diseases by controlling overactivation of the immune system 27 . Thus, mice deficient in BACH2 have both a paucity of T reg cells and an excess of memory/effector T cells that age and die prematurely, resulting in autoimmunity.
Structurally, BACH2 contains a BTB/POZ domain that mediates homo-and heterodimerization at its N terminus, and a bZIP domain at the C terminus that is required for DNA binding. The dimerization domain is an α-helical structure that contains a cysteine residue capable of forming a disulfide bond with its opposite partner 28 . Thus homodimerization is likely to be stabilized by a covalent modification that occurs soon after protein folding. BACH2 dimers translocate to the nucleus, where they interact with target DNA loci at palindromic Maf recognition elements, either alone or in collaboration with other members of the bZIP family, such as the small Maf proteins (MafF, MafG and MafK) 16 . This interaction-for example, at the mouse Prdm1 locus that encodes BLIMP1-represses gene expression.
Here we describe a novel PID caused by haploinsufficiency of BACH2, and propose a shared genetic mechanism to explain why some genes are particularly likely to be associated with disease caused by haploinsufficiency. We conclude that the interpretation of heterozygote variants in these genes should be regarded as significant and should be prioritized in any investigation of novel genetic disease by whole-exome sequencing.
RESULTS

BACH2 mutations are associated with CVID and colitis
We investigated a woman ( Fig. 1a,b ; family A) with infancy-onset colitis who became ill at 19 years old with noninfectious fever, splenomegaly (21.7 cm, compared with 10-12 cm in healthy adults) (Fig. 1c) and pancytopenia. Fever and cytopenia improved with corticosteroids, but lymphopenia, immunoglobulin deficiency (IgM, IgG, IgA and IgE), ongoing colitis, lung infiltrates and recurrent upper respiratory tract infections persisted (Fig. 1c , Table 1 and Supplementary  Table 1) . A colonic biopsy showed inflammatory changes with crypt branching and prominent lymphocytic infiltrates around the crypts (Fig. 1d) , with significantly reduced numbers of FoxP3 + T reg cells compared with those in healthy controls or subjects with classical inflammatory bowel disease (IBD) (Fig. 1e) . The early disease onset and unusual symptoms combined with the absence of family history prompted us to carry out whole-exome sequencing on this subject and her healthy parents as a trio. After we had excluded all variants with minor allele frequencies of >0.01, no candidate variants remained to support a hypothesis of recessive inheritance. We found a novel heterozygous de novo, nonsynonymous mutation in BACH2, c.T71C, that was predicted to be deleterious (Supplementary Table 2 ), substituting a highly conserved leucine by proline (L24P), and was not present in healthy family members ( Fig. 1b and Supplementary  Fig. 1) . A second family (family B) that had been previously investigated by exome sequencing (Fig. 1a) was found to have a heterozygous point mutation in BACH2, c.G2362A (Fig. 1b) , in which glutamic acid was substituted by lysine (E788K), in a father and daughter, both of whom presented with inflammation of both small and large bowel, as well as pulmonary disease including recurrent sino-pulmonary infections, bronchiectasis and fibrosis ( Fig. 1c and Supplementary Table 1) . The BACH2 mutation was not seen in healthy family members (Supplementary Fig. 1 ). The father (proband) was deficient in all immunoglobulin subtypes; the daughter had undetectable levels of IgA (Supplementary Table 1) . Detailed clinical features are described in Supplementary Note 1, Table 1 and Supplementary Figure 1 . We found no low-minor-allele-frequency variants or causative mutations in genes that cause monogenic IBD or other recognized PIDs [29] [30] [31] .
In the lymphocytes of affected individuals, we found decreased expression of FoxP3 in CD4 + CD25 hi CD127 lo T reg cells (Fig. 2a) , and increased expression of the type 1 helper T cell (T H 1 cell) TF T-bet and two gut-homing receptors, CCR9 and β 7 integrin, on CD4 + T cells 32, 33 ( Fig. 2b) . In B cells from these subjects, we found a marked reduction in CD19 + CD27 + memory and IgG class-switched CD27 + IgG + B cells (Fig. 2c) . These features were not present in healthy controls or in subjects with IBD ( Supplementary Fig. 2a) . Furthermore, numbers of CD24 + CD38 + transitional B cells were increased in affected subjects (Supplementary Fig. 2b) . In vitro activation of naive B cells from affected individuals resulted in significantly impaired plasmablast generation, CSR and class-switched antibody secretion in the presence of IL-21 (Fig. 2d,e) , which suggested a defect in B cell maturation toward memory and plasma cells, similar to that seen in Bach2-knockout mice 34 . Polyclonal activation of T cells resulted in reduced CD4 + T cell proliferation compared with that in healthy controls ( Supplementary  Fig. 2c ). In summary, the immunophenotype of individuals with mutations in BACH2 consisted of compromised T reg cells, enhanced T H 1 cell differentiation, impaired proliferation and defective maturation of B cells, and immunoglobulin class-switching.
BACH2 silencing mimics immunodeficient cell phenotypes
We next measured BACH2 protein expression by flow cytometry and found that it was reduced in CD4 + , CD8 + and B lymphocytes in affected subjects, despite normal mRNA expression in these people compared with that in healthy controls (Fig. 3a,b) . We measured the protein expression of Flag-tagged vectors encoding wild-type or mutant forms of BACH2 in transfected HEK293T cells and found that mutant forms of the protein accumulated less than the wild-type protein (Fig. 3c) at all time points measured and concentrations of vector used ( Supplementary Fig. 3a,b) . PRDM1, which encodes the protein BLIMP1, is a target of BACH2-mediated transcriptional repression 24 . We found that naive B cells and CD4 + T cells from affected subjects expressed significantly higher levels of PRDM1 mRNA than observed in healthy controls, which suggested a release from BACH2 repression (Figs. 3d,e) . Furthermore, this difference could be reversed by forced expression of wild-type BACH2 in CD4 + lymphocytes of affected subjects (Fig. 3e) . These observations suggested a causal relationship between reduced BACH2 expression and cellular phenotype. To confirm this relationship, we silenced BACH2 expression in T and B cells from healthy controls by ~50% via RNA interference (RNAi) and carried out functional phenotyping ( Supplementary Fig. 4a,b) . BACH2 silencing in control CD4 + T cells led to a significant increase in PRDM1 mRNA expression (Fig. 3f) and resulted in reduced proliferation of CD4 + T cells (Supplementary Fig. 4c ) compared with that in healthy controls, similar to what we observed in primary CD4 + T cells from affected subjects (Supplementary Fig. 2c ). In addition, BACH2 silencing in B cells from healthy controls significantly suppressed in vitro CSR toward the IgG and IgA isotypes (Fig. 3g) . Thus, experimental silencing of BACH2 in healthy T and B cells recapitulated the phenotype seen in primary cells of affected subjects.
BACH2 mutations impair protein stability
Both of the mutations that we identified affect highly conserved amino acid residues in BACH2 (Fig. 4a) . Mouse and human BACH2 share 90% sequence identity, and Leu24 is conserved across species and across other members of the BTB/POZ domain family ( Supplementary Fig. 5a ,b and Supplementary Table 2 ). Leu24 resides within α-helix 1 (residues 18-34) of the BTB/POZ domain, a key part of the BACH2 homodimerization interface (Fig. 4b,c) . The mutant proline residue probably perturbs α-helix 1 of the BTB/POZ domain and places a polar residue into the hydrophobic face of that helix, which we predicted would decrease dimer stability (Supplementary Table 2 ). We expressed and purified the BTB domains from both wild-type and L24P mutant proteins. The wildtype protein was soluble and formed dimers (Fig. 4d) , whereas the L24P mutant was insoluble in solution, was probably misfolded, and formed multiple aggregated species (Fig. 4e) . Glu788, the site of the C-terminus mutation, was again highly conserved (Supplementary ) quantification (right) from four low-power fields per patient (500-3,000 CD3 + cells counted per low-power field). Scale bars, 100 µm (main image) or 2 µm (inset). *P < 0.05, **P < 0.01, t-test.
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VOLUME 18 NUMBER 7 JULY 2017 nature immunology A r t i c l e s Fig. 5a ). Though it has not been characterized by structural studies, it is in proximity to a nuclear export signal (Fig. 4a) . We found that wild-type BACH2 protein was evenly distributed in both cytoplasm and nucleus, whereas the E788K mutant protein aggregated in the cytoplasm, with relatively little found in the nucleus ( Fig. 4f and Supplementary Movies 1 and 2). We observed similar protein 
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C o n t r o ls P a t ie n t s C o n t r o ls P a t ie n t s C o n t r o ls P a t ie n t s C o n t r o ls C o n t r o ls P a t ie n t s C o n t r o ls C o n t r o ls P a t ie n t s C o n t r o ls C o n t r o ls P a t ie n t s C o n t r o ls C o n t r o ls P a t ie n t s C o n t r o ls P a t ie n t s C o n t r o ls P a t ie n t s C o n t r o ls P a t ie n t s aggregates in HEK293T cells transfected with this C-terminal variant ( Supplementary Fig. 5c and Supplementary Movies 3 and 4). By contrast, aggregates were not detected in lymphocytes from patient A.II.1 that expressed the L24P mutant, although, as noted, expression levels of L24P-mutant BACH2 protein were lower than BACH2 expression levels in controls ( Supplementary Fig. 5d ). Thus, both gene mutations impair BACH2 protein stability.
BACH2 mutations are not dominant negative
In both families studied, the BACH2 gene mutations had the potential to act in a dominant negative manner. To investigate this, we cotransfected HEK293T cells with Flag-tagged wild-type protein together with constructs expressing untagged wild-type or mutant BACH2.
Neither mutant altered wild-type protein expression (Fig. 5a) .
We repeated the experiment with HEK293T cells cotransfected with vectors encoding two tagged (hemagglutinin (HA)-BACH2 and Flag-BACH2) forms of the wild-type protein together with constructs encoding untagged wild-type or mutant BACH2 protein (Fig. 5b) . Coimmunoprecipitation studies showed that untagged wild-type BACH2, but not mutant forms of the protein, interfered with dimerization between HA-and Flag-tagged wild-type BACH2. Furthermore, when we cotransfected Flag-tagged wild-type BACH2 with HA-tagged wild-type, L24P-mutant or E786K-mutant BACH2, we detected reduced amounts of mutant HA-BACH2 bound to Flagtagged wild-type BACH2 after immunoprecipitation, in proportion to the reduction in protein accumulation, which implied limited, if any, effects on wild-type BACH2 (Supplementary Fig. 6a ). All these results were consistent with our earlier findings of loss of stability of the mutant proteins compared with the wild-type protein (Fig. 4) . Finally, we used retroviral constructs encoding wild-type or mutant mouse BACH2 to transduce Prdm1-YFP transgenic CD4 + T cells. Forced expression of wild-type BACH2 alone led to a significant reduction in the expression of Prdm1-YFP, but cotransduction with either mutant form of BACH2 did not interfere with repression of the Prdm1 reporter in primary mouse lymphocytes (Fig. 5c) . Collectively, these data indicate that neither BACH2 mutation exerted a dominant negative effect.
Bach2 +/− mice have impaired lymphocyte development
In the absence of a dominant negative effect, we turned to haploinsufficiency as an explanation. A complete absence of Bach2 in mice results in B cell immunodeficiency and fatal autoimmunity later in life 15, 16 . If haploinsufficiency were responsible for the defects in lymphocyte development observed in our affected subjects, we would expect to see a similar effect in mice heterozygous for wild-type and null alleles (Bach2 +/− ). We found that Bach2 +/− mice had reduced Bach2 mRNA expression (Fig. 6a ) and protein expression (Fig. 6b) , as well as elevated Prdm1 mRNA expression (Supplementary Fig. 7a ). There was no difference in the numbers of CD4 + and CD8 + T cells, B cells or plasma cells between heterozygous and wild-type unchallenged mice (Supplementary Fig. 7b,c) , but Bach2 +/− mice did show a small but significant reduction in the number of FoxP3 + cells, as well as significant increases in numbers of CCR9 + and β 7 integrin + cells among CD4 + T cells (Fig. 6c-e) . We next immunized wild-type and plasma cells compared with that in wild-type mice (Fig. 6f) . The proportion of germinal-center B220 + Ki67 + Bcl-6 + B cells was also reduced in Bach2 +/− mice compared with that in wild-type mice (Fig. 6g) , thus supporting a haploinsufficiency model.
SE-regulated genes are associated with haploinsufficiency
Taken together, our data argue that the maintenance of a threshold concentration of BACH2 is crucial for proper immunoregulation. Mutations in other TF-encoding genes have been reported to cause haploinsufficiency disorders 35 . BACH2 expression is regulated in a complex manner, and the BACH2 locus contains an archetypal SE [12] [13] [14] 16, 36, 37 (Fig. 7a) . We therefore hypothesized that SE structure may be enriched among genes associated with haploinsufficiency diseases. To investigate this, we compared genetic disorders mediated by haploinsufficiency (372 genes) or autosomal recessive (AR) inheritance (259 genes) to haplosufficient (HS) gene states (i.e., those for which single-allele deletions are inconsequential; 901 genes) 38 (Online Methods). To validate these three groups, we evaluated the probability of loss-of-function intolerance (pLI) (as estimated by ExAc 39 ), for which a score of 0 predicts that the loss of a single copy of the gene is well tolerated, and a score of 1 predicts that the loss of a single copy is poorly tolerated and likely to result in a disease. As expected, the median pLI score for our haploinsufficiency list was considerably higher than for the others (median values of 0.86, 0.0005 and 0.004 for haploinsufficiency, HS and AR genes, respectively) (Fig. 7b) . Moreover, haploinsufficiency genes were substantially more likely to have SE architecture, as reflected by especially high acetylation of histone H3 on lysine 27 (H3K27ac), a hallmark of active enhancers 40 (Fig. 7c,d, Supplementary Fig. 8a and Supplementary Tables 3 and 4) . In contrast, there were no differences in the frequency of typical enhancers among the three groups (Fig. 7d) . We next compared the functions of genes among the three groups and found that haploinsufficiency genes were more likely to encode TFs compared with genes associated with AR inheritance or HS genes ( Fig. 7e and Supplementary Fig. 8b,c) . To address any potential confounding abundance of TF-encoding genes in SEs, we also divided our list of haploinsufficiency genes into those that code for TFs and those that code for all other proteins, and compared the frequency of SEs (Supplementary Fig. 8c ). We found that even after TF genes were discounted, haploinsufficiency-disease-causing genes were heavily enriched for SE architecture compared with HS and AR genes (Supplementary Fig. 8d ). We next asked whether SE-bearing genes have less tolerance to loss-of-function mutations and whether the 'size' of the SE correlates with this effect. We expanded our analysis to a collection of genes regulated by SEs from across more than 100 tissues (dbSuper database 41 ) and observed both a striking increase in the pLI score with increasing SE signal size and a concomitant increase in the proportion of TF genes (Fig. 7f) . Thus, not only the presence of an SE but also its 'size' correlates with the likelihood of disease caused by haploinsufficiency. SE architecture was previously shown to be associated with human disease loci in GWAS 14, 36, 42 . This is the case for the BACH2 gene 16, 22 , which was consistently in the top 1% of human SE genes as ranked by H3K27ac SE signal intensity in naive CD4 + T cells and naive CD8 + T and B cells (Supplementary Fig. 8e-g ). On the basis of the SE enrichment among haploinsufficiency genes, we next asked whether there would be general enrichment of GWAS 'hits' in genes associated with haploinsufficiency disease. In agreement with this hypothesis, A r t i c l e s we found highly significant enrichment of disease-associated single-nucleotide variants in this gene set ( Fig. 7g and Supplementary Table 5 ). To exclude gene size as a potential confounding factor, we repeated the analysis on subsets of genes of less than 50 kb, and again we found more GWAS associations in genes associated with haploinsufficiency syndromes than in HS genes ( Supplementary  Fig. 8h) . Thus, haploinsufficiency genes are enriched for both SEs and GWAS hits.
DISCUSSION
Adaptive immunity is critically dependent on the appropriate differentiation and maturation of lymphocytes. Several complex differentiation steps are required for the formation of mature cells that occupy specific niches and carry out defined roles within the immune system. Key to the regulation of lymphocyte differentiation is precise control over the expression of many TFs that form complex regulatory networks. The identification of both mice and humans with dramatic early-onset stereotypical autoimmune disease associated with a homozygous loss of gene expression has led to the identification of many key regulatory TFs, most notably FoxP3, the master TF of T reg cells 27 . Reductions in the cost and time requirements of whole-exome sequencing have allowed subjects with no family history of disease to be analyzed for genetic mutations. Comparing a person's DNA sequence with those of his or her healthy parents can identify the appearance of de novo mutations that would otherwise be missed if a positive family history were required before any investigation could take place. Through this strategy, a number of heterozygous mutations associated with autoimmune diseases have recently been discovered.
BACH2 has a major role in the regulation of the adaptive immune system. Its own expression is tightly regulated by the presence of a large SE region within the Bach2 locus 14 . The role of BACH2 has been elucidated through the investigation of BACH2-deficient mice that have defects in B cell CSR and T reg cell differentiation. In mice, this combination results in chronic variable immunodeficiency with a late-onset, progressively fatal autoimmune syndrome that includes inflammatory enteropathy and respiratory infiltrates 15 . In humans, in line with BACH2's designation as an SE-associated gene, there is a link between single-nucleotide polymorphisms within the BACH2 locus and a number of autoimmune and inflammatory diseases.
Herein we describe three subjects from two families that have heterozygous mutations in BACH2. Two of the three presented with earlyonset autoimmune gastrointestinal disease, and the third presented with symptoms later in life. All three developed a chronic variable immunodeficiency characterized by recurrent respiratory tract infections associated with an inability to generate appropriate antibody responses to vaccination. Our findings support a role for human BACH2 as a key regulator of the human adaptive immune system critical to the maintenance of T reg cell function and B cell maturation. BACH2-deficient mice show accelerated T cell senescence 26, 43 , and, in keeping with this, T cells from our subjects showed defective cell proliferation associated with progressive T cell lymphopenia. Many of the autoimmune phenomena in our subject with the L24P mutation have been successfully treated with corticosteroids, although this has not reduced her chronic variable immunodeficiency or her pneumonitis, which is of some concern, as this is a key cause of early mortality in BACH2-deficient mice. The father with the E788K mutation developed bronchiectasis later in life. It remains to be seen whether the pneumonitis will be progressive in our L24P subject and result in chronic lung damage. In the first family, the BACH2 T71C gene mutation resulted in a protein that is predicted to be unable to dimerize and is unstable. In the second family, the mutant protein encoded by BACH2 E788K again showed some evidence of a defect in stability, albeit less dramatic, and we saw more evidence of a defect in the localization of the protein, with reduced nuclear localization. We found little evidence that either mutant protein acted in a dominant negative manner. Thus we attribute the clinical phenotype to BACH2 haploinsufficiency, and this conclusion is consistent with our findings and previous reports 44 that Bach2 +/− heterozygotes have defects in CSR antibody responses.
Mammalian cells contain tens of thousands of gene enhancer sites that cluster in large numbers around a select subset of genes that make up some 5-10% of the total human genome. These clusters are collectively known as SEs. Mutations identified in GWAS tend to associate with these gene loci, but the significance of this remains unclear. Previous work suggests that SE genes encode proteins with functions that are highly dependent on transcription, small changes in which would lead to significant changes in cell development. On this basis, we hypothesize that SE genes would be susceptible to gene dosage effects in patients with heterozygous mutations. We conclude that the relationship between GWAS and SE-regulated genes exists not simply because these genes transcribe proteins that are important per se, but because small changes in the expression of SE genes result in large functional changes in the affected cells.
In summary, we describe a newly recognized disorder, BACH2-related immunodeficiency and autoimmunity (BRIDA), that is caused by heterozygous mutations in BACH2. We found that the mechanism of disease is BACH2 haploinsufficiency, and that BACH2 is a prototype haploinsufficiency gene with SE architecture. Given the prevalence of heterozygous variants in nonconsanguineous human genomes 45 , it is difficult to predict which ones cause disease. We have demonstrated that haploinsufficiency diseases are associated with heterozygous mutations in SE-regulated genes. As SEs allow complex regulation of gene transcription, we conclude that haploinsufficiency A r t i c l e s genes are carefully regulated owing to their SE association, and that small changes in their expression level can potentially lead to amplified changes in their associated network, especially for TF-encoding genes, thereby resulting in significant pathology. Thus, SE-regulated genes should be a higher priority in assessments of heterozygous variants discovered by whole-exome/genome sequencing.
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper. Live-Dead Flixable Aqua Dead Cell stain was from Thermo Fisher (Boston, MA, USA). Raji, Ramos and HEK293T cell lines were from ATCC. Unless specified, human cells and cell lines were maintained in RPMI 1640 media supplemented with 2 mM L-glutamine (Life Technologies), penicillin and streptomycin (100 IU/mL and 100 µg/mL, respectively; Life Technologies), and 10% FBS (Atlanta Biologicals). Mouse cells were cultured in identical medium supplemented with 2 mM β-mercaptoethanol (Sigma Aldrich). HEK293T cells were maintained in DMEM (Life Technologies) supplemented as done for the human cell culture medium. Cell lines were not tested for mycoplasma contamination.
Mice. C57BL/6J mice were from The Jackson Laboratory. Bach2 −/− and Bach2 +/− mice were generated and housed as previously described 15 . BLIMP1-YFP BAC transgenic mice have been previously described 46 . No statistical methods were used to predetermine sample size.
Cell isolation and culture. We isolated human peripheral blood mononuclear cells (PBMCs) from the blood of affected subjects and healthy donors by density-gradient centrifugation using Ficoll (GE Healthcare), and we lysed red blood cells with RBC lysis buffer (eBioscience 47 . CD4 + T cells from the spleens and lymph nodes of 6-8-week-old mice were purified by negative selection and magnetic separation (Miltenyi), and then the naive CD4 + CD25 − CD62L + CD44 − population was sorted with a FACSAria II. Naive BLIMP1-YFP CD4 + T cells were activated for 3 d by plate-bound anti-CD3 (2C11; BioXCell) and anti-CD28 (37.51; BioXCell), each at a concentration of 10 µg/ml in medium. Cells were stimulated in the presence of mouse IL-12 (20 ng/ml) and anti-mouse IL-4 (10 µg/ml) (T H 1 cell conditions) (both from R&D Systems) for 3 d, then split into fresh uncoated plates and supplemented with fresh medium and 100 IU/mL human IL-2 (NIH/NCI BRB Preclinical Repository).
B cell cultures and induction of class-switch recombination. Purified naive B cells were cultured in RPMI 1640 media containing L-glutamine (Sigma Aldrich, St. Louis, MO, USA), 10% FBS (Sigma Aldrich), 10 mM HEPES, pH 7.4 (Sigma-Aldrich), 0.1 mM nonessential amino acid solution (Sigma-Aldrich), 1 mM sodium pyruvate and 40 µg/ml apo-transferrin (Sigma-Aldrich), and supplemented with 60 µg/ml penicillin and 100 µg/ml streptomycin. To induce CSR, we added recombinant human CD40L (1 µg/ml; R&D Systems, Minneapolis, MN, USA), Fab fragment anti-human IgM (Jackson Immunoresearch, West Grove, PA, USA), IL-2 (100 IU/ml; PeproTech, Rocky Hill, NJ, USA) and IL-21 (50 ng/ml; PeproTech) at the beginning of the culture. Cells were cultured in 96-well round-bottom plates (Nunc, Roskilde, Denmark) for 5 d. Culture supernatants were collected for ELISA at the end of the culture period.
IgG and IgA ELISA. IgG and IgA secretion was assessed with the Ready-setgo total IgG and IgA kits (Thermo Fisher) according to the manufacturer's protocols. Absorbance was read at 450 nm within 30 min of the end of the reaction. The sensitivities and linear ranges were obtained with the standard immunoglobulin provided with the kit.
Whole-exome sequencing. DNA was extracted from EDTA-treated blood with the Maxwell 16 blood DNA purification kit (Promega) or from PBMCs with the DNeasy Blood & Tissue kit (Qiagen). A total of 3 µg of DNA was sheared with an E220 focused sonicator (Covaris), and exome libraries were generated with the SureSelect Human All Exon kits (Agilent) according to the manufacturer's protocol. The quality of generated libraries was inspected with the Agilent High Sensitivity DNA kit (Agilent) and quantified with a qPCR kit (Agilent). Samples were sequenced on an Illumina HiSeq 2000 (Illumina) to generate 100-bp paired-end reads. Sequences were aligned to human reference genome GRCh37 with bwa v.0.6.1 with the default parameters 48 . Variant calling (single-nucleotide variants and insertions/deletions) was done with the GATK v.2 toolkit 49 , and variants were annotated with Annovar 50 . An in-house custom analysis pipeline was used to filter and prioritize variants on the basis of the likely genetic models and clinical pedigree for patients.
Sanger sequencing. DNA samples were extracted from blood or saliva with the Maxwell 16 blood DNA purification kit (Promega) or Oragene DNA (OG500) (Oragene), respectively. The candidate mutations in affected and unaffected individuals from both families in the study were validated with the BigDye Terminator sequencing kit (Life Technologies) and sequenced on an ABI3730xl genetic analyzer (Applied Biosystems). PCR primer sequences are available from the corresponding author(s) on request.
Flow cytometry. All flow cytometry was carried out in a final staining volume of 100-200 µL, with data acquisition on an LSR II, LSRFortessa or FACSVerse (all BD Biosciences) within 24 h. Appropriate internal controls, isotype controls and FMO (fluorescence minus one) controls were used to assign gates. Rat anti-mouse CD16/CD32 (clone 2.4G2; BD Biosciences) was used for Fc blockade in mouse flow cytometry experiments. FACS data were analyzed with FlowJo (Tree Star Inc.). For intracellular staining, a BD Cytofix/Cytoperm plus Fixation/Permeabilization Solution Kit was used according to the manufacturer's instructions. For cytokine staining, 4 h of re-stimulation with the phorbol ester PMA (50 ng/mL) and ionomycin (1 mM) (both Sigma) in the presence of brefeldin A (GolgiPlug (BD Biosciences)) was carried out before fixation and permeabilization. FoxP3 staining was carried out with the kit from eBiosciences as per the manufacturer's instructions. We calculated relative FoxP3 and BACH2 levels by dividing the geometric mean fluorescence intensity of patient cells by that of the matched healthy control cells in each run. For assessment of cell proliferation by flow cytometry, T cells were stained with CellTrace Violet as per the manufacturer's instructions and then cultured in the presence of anti-CD3 and anti-CD28 (1 µg/mL of each; clones HIT3α and CD28.2, respectively, both from Biolegend) for 5 d before live/dead staining and data acquisition.
In vivo class-switch assay. We injected 8-10-week-old Bach2 +/− heterozygous and Bach2 +/+ wild-type mice intraperitoneally with 50 µg of NP-CGG (Biosearch Technologies) 1:1 in alum (Thermo Scientific) (vol/vol). We collected spleens after 8 d and made single-cell suspensions by passing the cells through a 40-µm strainer. We then carried out surface staining and flow cytometry as described above.
Quantitative RT-PCR. Total RNA was extracted with TRIzol reagent (Invitrogen) and treated with DNase I (Qiagen). RNA was reverse-transcribed to cDNA with the iScript cDNA synthesis kit (Bio-Rad) according to the manufacturer's instructions. Quantitative real-time PCR (qRT-PCR) experiments were carried out in triplicate with Taqman Universal PCR Master Mix (Applied Biosystems) in total reaction volumes of 20 µL and thermocycled in a CFX284 Touch real-time PCR detection system (Bio-Rad). The following Taqman gene-specific primer probes were purchased from Applied Biosystems: human BACH2 (Hs00222364_m1), PRDM1 (Hs00153357_m1), ACTB (Hs99999903_m1) and 18S ribosomal RNA (Hs99999901_s1); and mouse Bach2 (Mm00464379_m1), Prdm1 (Mm00476128_m1), Bcl6 (Mm00477633_m1) and Actb (Mm00607939_s1). Cycle threshold (C t ) values were exported and normalized against the control probe via the 2 −∆Ct method and are reported as expression relative to a control condition.
Silencing of BACH2 and BACH2 overexpression. 5 × 10 6 PBMCs per sample were nucleofected with 300 nM Dicer-substrate short interfering RNA (DsiRNA) negative control or predesigned BACH2 DsiRNA (both TriFECTa; Integrated DNA Technologies) with the Amaxa human T cell nucleofector kit (Program-U014; Lonza) according to the manufacturer's instructions. 24 h after nucleofection, cells were labeled with the CellTrace Violet cellproliferation kit (Thermo) and rested for 6 h in culture before activation of 1 × 10 5 cells per 96-well plate with plate-bound anti-CD3 (1 µg/ml; clone HIT3α) and anti-CD28 (1 µg/ml; clone CD28.2) (both from BioLegend). Cells were surface-stained and proliferation was analyzed by flow cytometry after 5 d.
Naive B cells or CD4 + T cells were nucleofected with 2 µM MISSION universal negative control siRNA (Sigma) or BACH2 siRNA (Hs01_00214431; Sigma) with the P3 primary cell 96-well Nucleofector kit (Lonza) according to the manufacturer's instructions. Cells were cultured for 24 h at 37 °C in the presence of 100 ng/ml human IL-7 before activation for CSR as described above.
5 × 10 6 blasting human CD4 + T cells were mixed with 2-5 µg of either BACH2 or eGFP mRNA (TriLink) in 50 µl of HyClone MaxCyte buffer and electroporated in an OC-100 PA electroporation chamber with a MaxCyte GT instrument (program T-02). After electroporation, cells were incubated for 20 min at 37 °C in electroporation buffer in 96-well plates and then transferred to 12-well plates in complete RPMI media containing 100 IU/ml human IL-2. PRDM1 expression was analyzed after 24-48 h by qPCR.
Plasmid DNA and point mutagenesis. Wild-type Bach2 cDNA expression vectors pMSCV-IRES-GFP (pMIGR1-Bach2) and pMSCV-IRES-Thy1.1 DEST (pMIT-Bach2) have been described previously 15 . We carried out gene synthesis to achieve an N-terminal fusion of Flag and HA sequences preceded by a methionine translation-initiation codon (MDYKDDDDK and MYPYDVPDYA, respectively) to the wild-type BACH2 open reading frame. Synthesized DNA was subcloned into pMIT to generate pMIT-Flag-BACH2 and pMIT-HA-BACH2. Point mutagenesis to introduce the Bach2 T71C (Bach2 L24P ) and Bach2 G2356A (Bach2 E786K ) mutations was carried out with the Agilent QuickChange II XL site-directed mutagenesis kit (Agilent Technologies) according to the manufacturer's instructions, with the following primer pairs: Bach2 T71C : forward, 5′-CATTGAGGCCCAGGGGGATGTTGGCACAG-3′ and reverse, 5′-CTGTGCCAACATCCCCCTGGGCCTCAATG-3′; Bach2 G2356A : forward, 5′-AGAGGTACAATTCTTAGAGGTGTTGCTGGGCACC-3′ and reverse, 5′-GGTGCCCAGCAACACCTCTAAGAATTGTACCTCT-3′.
Transfection and production of retrovirus. Transfection was carried out in antibiotic-free medium with Lipofectamine LTX and Plus reagent (Invitrogen). Medium was replaced 7 h later. For retrovirus production, payload retroviral plasmid was cotransfected with pCL-Eco helper virus plasmid as described 51 . Transfected cells were harvested and viral supernatant was collected 48 h after transfection.
Retrovirus transduction. Prdm1-YFP BAC transgenic CD4 + T cells were activated for 24 h with plate-bound anti-mouse CD3 (145-2C11; Biolegend) and anti-mouse CD28 (37.51; Biolegend). Activated cells were transduced with supernatants that contained retrovirus encoding Thy1.1 alone (EV) or together with mouse Bach2 or mutant mouse Bach2 conforming to the L24P or E786K mutation, in the presence of polybrene (4 µg/ml), by centrifugation at 2,200 r.p.m. for 50 min at 22 °C. Medium was replaced afterward with fresh culture medium, and cells were harvested 48 h after transduction.
